<DOC>
	<DOCNO>NCT02754167</DOCNO>
	<brief_summary>Anticalins® engineer human protein able bind specific target molecule . The Anticalin PRS-080 # 022-DP investigate study direct hepcidin intend treatment anemia chronic disease . This Phase Ib study shall investigate safety , pharmacokinetics pharmacodynamics single administration PRS-080 # 022-DP anemic stage 5 chronic kidney disease patient undergoing hemodialysis .</brief_summary>
	<brief_title>Phase Ib Study Evaluate PRS-080 Anemic Chronic Kidney Disease Patients</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , placebo-controlled , single ascend dose phase Ib study anemic stage 5 chronic kidney disease patient require hemodialysis . Eligible subject undergo screen assessment PRS-080 # 22-DP administer intravenous infusion . The study consist 3 dose cohort 2 mg/kg , 4 mg/kg , 8 mg/kg body weight 8 subject cohort . Using standard 6+2 design , 6 subject cohort randomize PRS-080 # 022-DP 2 subject cohort randomize placebo . The decision escalate dose base interim analysis clinical safety safety laboratory data . Safety tolerability , pharmacokinetics , pharmacodynamics well potential immunogenicity investigate .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hepcidins</mesh_term>
	<criteria>Patients stage 5 chronic kidney disease hemodialysis least 90 day Patients stable erythropoiesisstimulating agent ( ESA ) dose Hemoglobin ( Hb ) 9 11 g/dL Ferritin ≥ 300 ng/mL . Transferrin saturation ( TSAT ) ≤ 30 % Hepcidin 5 50 nmol/L Anemia due cause chronic kidney disease , include hemoglobinopathy , hemolytic anemia , myelodysplasia malignancy Blood transfusion within 2 month administration study medication . Iron treatment 1 week study medication administration 1 week study medication administration . Previous enrollment study Current previous ( within 60 day study medication administration ) treatment another investigational drug and/or medical device participation another clinical study . Pregnancy breastfeed woman child bearing age . Known allergy component PRS080 # 022DP formulation Positive hepatitis B surface antigen , antihepatitis C virus antibody , human immunodeficiency virus Planned surgery study period Unwilling unable comply protocol , judgment investigator Unstable angina , myocardial infarction , percutaneous transluminal coronary angioplasty/stents , apoplexy coronary artery bypass graft &lt; 3 month prior screen . Congestive heart failure : New York Heart Association Class III IV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Hepcidin</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>iron</keyword>
	<keyword>anemia chronic disease</keyword>
</DOC>